You just read:

DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies

News provided by

Janssen Biotech, Inc.

Jun 16, 2017, 14:15 ET